A Complement-Optimized EGFR Antibody Improves Cytotoxic Functions of Polymorphonuclear Cells against Tumor Cells

Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2

(2015) Eric F. Zhu et al.   CANCER CELL

Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer

(2015) R. Dienstmann et al.   Cancer Discovery

Complement in Antibody-Based Tumor Therapy

(2014) Stefanie Derer et al.   CRITICAL REVIEWS IN IMMUNOLOGY

Expression and regulation of complement receptors by human natural killer cells

(2014) Xiaoyun Min et al.   IMMUNOBIOLOGY

Complement Component C5 Recruits Neutrophils in the Absence of C3 during Respiratory Infection with Modified Vaccinia Virus Ankara

(2014) Philip J. R. Price et al.   JOURNAL OF IMMUNOLOGY

Epidermal Growth Factor Receptor Targeting IgG3 Triggers Complement-Mediated Lysis of Decay-Accelerating Factor Expressing Tumor Cells through the Alternative Pathway Amplification Loop

(2014) T. Rosner et al.   JOURNAL OF IMMUNOLOGY

A Second Stimulus Required for Enhanced Antifungal Activity of Human Neutrophils in Blood Is Provided by Anaphylatoxin C5a

(2014) Kerstin Hünniger et al.   JOURNAL OF IMMUNOLOGY

Complement Is Activated by IgG Hexamers Assembled at the Cell Surface

(2014) C. A. Diebolder et al.   SCIENCE

Increasing FcγRIIa affinity of an FcγRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity

(2013) Stefanie Derer et al.   mAbs

Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy

(2012) L. Bologna et al.   JOURNAL OF IMMUNOLOGY

Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer Patients

(2012) F. J. Beurskens et al.   JOURNAL OF IMMUNOLOGY

Opposing Roles for Complement Component C5a in Tumor Progression and the Tumor Microenvironment

(2012) L. Gunn et al.   JOURNAL OF IMMUNOLOGY

Chemokines and the Signaling Modules Regulating Integrin Affinity

(2012) Alessio Montresor et al.   Frontiers in Immunology

Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC

(2011) Roland Repp et al.   JOURNAL OF IMMUNOLOGICAL METHODS

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

(2011) Robert Pirker et al.   LANCET ONCOLOGY

Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies

(2010) A. Pievani et al.   BLOOD

Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer

(2010) Alberto Bardelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions

(2010) Gregory L. Moore et al.   mAbs

Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo

(2010) Yi-Fan Hsu et al.   Molecular Cancer

Complement: a key system for immune surveillance and homeostasis

(2010) Daniel Ricklin et al.   NATURE IMMUNOLOGY

Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model

(2009) S.-Y. Wang et al.   BLOOD

Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells

(2008) M. Peipp et al.   BLOOD

Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies

(2008) M. Dechant et al.   CANCER RESEARCH

Effector mechanisms of therapeutic antibodies against ErbB receptors

(2008) Matthias Peipp et al.   CURRENT OPINION IN IMMUNOLOGY

Modulation of the antitumor immune response by complement

(2008) Maciej M Markiewski et al.   NATURE IMMUNOLOGY

EGFR Antagonists in Cancer Treatment

(2008) Fortunato Ciardiello et al.   NEW ENGLAND JOURNAL OF MEDICINE